151 related articles for article (PubMed ID: 26984211)
21. Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.
Vitolo U; Ladetto M; Boccomini C; Baldini L; De Angelis F; Tucci A; Botto B; Chiappella A; Chiarenza A; Pinto A; De Renzo A; Zaja F; Castellino C; Bari A; Alvarez De Celis I; Evangelista A; Parvis G; Gamba E; Lobetti-Bodoni C; Ciccone G; Rossi G
J Clin Oncol; 2013 Sep; 31(27):3351-9. PubMed ID: 23960180
[TBL] [Abstract][Full Text] [Related]
22. [Experience with fludarabine treatment and review of the literature].
Telek B; Rejtó L; Kiss A; Batár P; Reményi G; Rák K; Udvardy M
Orv Hetil; 2002 Jun; 143(24):1459-65. PubMed ID: 12138643
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma.
McLaughlin P; Hagemeister FB; Swan F; Cabanillas F; Pate O; Romaguera JE; Rodriguez MA; Redman JR; Keating M
J Clin Oncol; 1994 Mar; 12(3):575-9. PubMed ID: 8120556
[TBL] [Abstract][Full Text] [Related]
24. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).
Forstpointner R; Unterhalt M; Dreyling M; Böck HP; Repp R; Wandt H; Pott C; Seymour JF; Metzner B; Hänel A; Lehmann T; Hartmann F; Einsele H; Hiddemann W;
Blood; 2006 Dec; 108(13):4003-8. PubMed ID: 16946304
[TBL] [Abstract][Full Text] [Related]
25. A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma.
Ogura M; Ando K; Suzuki T; Ishizawa K; Oh SY; Itoh K; Yamamoto K; Au WY; Tien HF; Matsuno Y; Terauchi T; Yamamoto K; Mori M; Tanaka Y; Shimamoto T; Tobinai K; Kim WS
Br J Haematol; 2014 Jun; 165(6):768-76. PubMed ID: 24617454
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
Hopfinger G; Nösslinger T; Lang A; Linkesch W; Melchardt T; Weiss L; Egle A; Greil R
Ann Hematol; 2014 Mar; 93(3):459-62. PubMed ID: 24441915
[TBL] [Abstract][Full Text] [Related]
27. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
[TBL] [Abstract][Full Text] [Related]
28. Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Tsimberidou AM; Younes A; Romaguera J; Hagemeister FB; Rodriguez MA; Feng L; Ayala A; Smith TL; Cabanillas F; McLaughlin P
Cancer; 2005 Jul; 104(2):345-53. PubMed ID: 15948158
[TBL] [Abstract][Full Text] [Related]
29. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
[TBL] [Abstract][Full Text] [Related]
31. Phase 1-2 study of vorinostat (SAHA), cladribine and rituximab (SCR) in relapsed B-cell non-Hodgkin lymphoma and previously untreated mantle cell lymphoma.
Spurgeon SE; Sharma K; Claxton DF; Ehmann C; Pu J; Shimko S; Stewart A; Subbiah N; Palmbach G; LeBlanc F; Latour E; Chen Y; Mori M; Hasanali Z; Epner EM
Br J Haematol; 2019 Sep; 186(6):845-854. PubMed ID: 31177537
[TBL] [Abstract][Full Text] [Related]
32. Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
McLaughlin P; Hagemeister FB; Rodriguez MA; Sarris AH; Pate O; Younes A; Lee MS; Dang NH; Romaguera JE; Preti AH; McAda N; Cabanillas F
Semin Oncol; 2000 Dec; 27(6 Suppl 12):37-41. PubMed ID: 11225999
[TBL] [Abstract][Full Text] [Related]
33. Prospective clinical study of R-CMD therapy for indolent B cell lymphoma and mantle cell lymphoma from the Hokuriku Hematology Oncology Study Group.
Sakai T; Masaki Y; Otsuki N; Sakamaki I; Kishi S; Miyazono T; Urasaki Y; Murakami J; Satoh T; Nakamura T; Iwao H; Nakajima A; Kawanami T; Miki M; Fujita Y; Tanaka M; Fukushima T; Okazaki T; Ueda T
Med Oncol; 2015 Sep; 32(9):232. PubMed ID: 26275804
[TBL] [Abstract][Full Text] [Related]
34. Low-grade non-Hodgkin's lymphoma--development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND).
Keating MJ; McLaughlin P; Cabanillas F
Eur J Cancer Care (Engl); 1997 Dec; 6(4 Suppl):21-6. PubMed ID: 9460339
[TBL] [Abstract][Full Text] [Related]
35. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
36. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
37. Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group.
Dimopoulos MA; Fountzilas G; Papageorgiou E; Kiamouris C; Mantzios G; Anagnostopoulos A; Nicolaides C; Economopoulos T;
Leuk Lymphoma; 2002 Jan; 43(1):111-4. PubMed ID: 11908713
[TBL] [Abstract][Full Text] [Related]
38. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.
Cohen BJ; Moskowitz C; Straus D; Noy A; Hedrick E; Zelenetz A
Leuk Lymphoma; 2001; 42(5):1015-22. PubMed ID: 11697618
[TBL] [Abstract][Full Text] [Related]
39. Fludarabine, mitoxantrone and dexamethasone as front-line therapy in elderly patients affected by newly-diagnosed, low-grade non-Hodgkin's lymphomas with unfavorable prognostic factors: results of a phase II study.
Bordonaro R; Petralia G; Restuccia N; Todaro AM; Serraino D; Giuffrida D; Cordio S; Giannitto-Giorgio C; Salice P; Ursino M; Novello G; Marletta F; Manusia M
Leuk Lymphoma; 2004 Jan; 45(1):93-100. PubMed ID: 15061203
[TBL] [Abstract][Full Text] [Related]
40. Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Janikova A; Koristek Z; Vinklarkova J; Pavlik T; Sticha M; Navratil M; Kral Z; Vasova I; Mayer J
Exp Hematol; 2009 Nov; 37(11):1266-73. PubMed ID: 19654036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
